159 related articles for article (PubMed ID: 22645700)
1. Activated Protein C Does Not Alleviate the Course of Systemic Inflammation in the APCAP Trial.
Kyhälä L; Mentula P; Kylänpää L; Moilanen E; Puolakkainen P; Pettilä V; Repo H
Int J Inflam; 2012; 2012():712739. PubMed ID: 22645700
[TBL] [Abstract][Full Text] [Related]
2. APCAP--activated protein C in acute pancreatitis: a double-blind randomized human pilot trial.
Pettilä V; Kyhälä L; Kylänpää ML; Leppäniemi A; Tallgren M; Markkola A; Puolakkainen P; Repo H; Kemppainen E
Crit Care; 2010; 14(4):R139. PubMed ID: 20663207
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of recombinant human activated protein C for severe sepsis.
Bernard GR; Vincent JL; Laterre PF; LaRosa SP; Dhainaut JF; Lopez-Rodriguez A; Steingrub JS; Garber GE; Helterbrand JD; Ely EW; Fisher CJ;
N Engl J Med; 2001 Mar; 344(10):699-709. PubMed ID: 11236773
[TBL] [Abstract][Full Text] [Related]
4. Drotrecogin alfa (recombinant human activated protein C) in severe acute pancreatitis.
Jamdar S; Siriwardena AK
Crit Care; 2005 Aug; 9(4):321-2. PubMed ID: 16137370
[TBL] [Abstract][Full Text] [Related]
5. Extended evaluation of recombinant human activated protein C United States Trial (ENHANCE US): a single-arm, phase 3B, multicenter study of drotrecogin alfa (activated) in severe sepsis.
Bernard GR; Margolis BD; Shanies HM; Ely EW; Wheeler AP; Levy H; Wong K; Wright TJ;
Chest; 2004 Jun; 125(6):2206-16. PubMed ID: 15189943
[TBL] [Abstract][Full Text] [Related]
6. Activated protein C retards recovery from coagulopathy in severe acute pancreatitis.
Kyhälä L; Lindström O; Kylänpää L; Mustonen H; Puolakkainen P; Kemppainen E; Tallgren M; Pettilä V; Repo H; Petäjä J
Scand J Clin Lab Invest; 2016; 76(1):10-6. PubMed ID: 26403265
[TBL] [Abstract][Full Text] [Related]
7. Procalcitonin, soluble interleukin-2 receptor, and soluble E-selectin in predicting the severity of acute pancreatitis.
Kylänpää-Bäck ML; Takala A; Kemppainen EA; Puolakkainen PA; Leppäniemi AK; Karonen SL; Orpana A; Haapiainen RK; Repo H
Crit Care Med; 2001 Jan; 29(1):63-9. PubMed ID: 11176162
[TBL] [Abstract][Full Text] [Related]
8. Drotrecogin alfa (activated) (recombinant human activated protein C) reduces host coagulopathy response in patients with severe sepsis.
Dhainaut JF; Yan SB; Margolis BD; Lorente JA; Russell JA; Freebairn RC; Spapen HD; Riess H; Basson B; Johnson G; Kinasewitz GT;
Thromb Haemost; 2003 Oct; 90(4):642-53. PubMed ID: 14515185
[TBL] [Abstract][Full Text] [Related]
9. Drotrecogin alfa (activated).
Lyseng-Williamson KA; Perry CM
Drugs; 2002; 62(4):617-30; discussion 631-2. PubMed ID: 11893230
[TBL] [Abstract][Full Text] [Related]
10. Biomarker response to drotrecogin alfa (activated) in children with severe sepsis: results from the RESOLVE clinical trial*.
Dalton HJ; Carcillo JA; Woodward DB; Short MA; Williams MD
Pediatr Crit Care Med; 2012 Nov; 13(6):639-45. PubMed ID: 22791090
[TBL] [Abstract][Full Text] [Related]
11. Safety, pharmacokinetics, and pharmacodynamics of drotrecogin alfa (activated) in children with severe sepsis.
Barton P; Kalil AC; Nadel S; Goldstein B; Okhuysen-Cawley R; Brilli RJ; Takano JS; Martin LD; Quint P; Yeh TS; Dalton HJ; Gessouron MR; Brown KE; Betts H; Levin M; Macias WL; Small DS; Wyss VL; Bates BM; Utterback BG; Giroir BP
Pediatrics; 2004 Jan; 113(1 Pt 1):7-17. PubMed ID: 14702440
[TBL] [Abstract][Full Text] [Related]
12. Cellular markers of systemic inflammation and immune suppression in patients with organ failure due to severe acute pancreatitis.
Kylänpää-Bäck ML; Takala A; Kemppainen E; Puolakkainen P; Kautiainen H; Jansson SE; Haapiainen R; Repo H
Scand J Gastroenterol; 2001 Oct; 36(10):1100-7. PubMed ID: 11589386
[TBL] [Abstract][Full Text] [Related]
13. Use of activated protein C has no avail in the early phase of acute pancreatitis.
Akay S; Ozutemiz O; Yenisey C; Simsek NG; Yuce G; Batur Y
HPB (Oxford); 2008; 10(6):459-63. PubMed ID: 19088933
[TBL] [Abstract][Full Text] [Related]
14. Effects of drotrecogin alfa (activated) on organ dysfunction in the PROWESS trial.
Vincent JL; Angus DC; Artigas A; Kalil A; Basson BR; Jamal HH; Johnson G; Bernard GR;
Crit Care Med; 2003 Mar; 31(3):834-40. PubMed ID: 12626993
[TBL] [Abstract][Full Text] [Related]
15. The potential role of procalcitonin and interleukin 8 in the prediction of infected necrosis in acute pancreatitis.
Rau B; Steinbach G; Gansauge F; Mayer JM; Grünert A; Beger HG
Gut; 1997 Dec; 41(6):832-40. PubMed ID: 9462219
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic-pharmacodynamic analysis of drotrecogin alfa (activated) in patients with severe sepsis.
Macias WL; Dhainaut JF; Yan SC; Helterbrand JD; Seger M; Johnson G; Small DS
Clin Pharmacol Ther; 2002 Oct; 72(4):391-402. PubMed ID: 12386641
[TBL] [Abstract][Full Text] [Related]
17. Decreased inflammation and improved survival with recombinant human activated protein C treatment in experimental acute pancreatitis.
Alsfasser G; Warshaw AL; Thayer SP; Antoniu B; Laposata M; Lewandrowski KB; Fernández-del Castillo C
Arch Surg; 2006 Jul; 141(7):670-6; discussion 676-7. PubMed ID: 16847238
[TBL] [Abstract][Full Text] [Related]
18. Inflammatory mediators in human acute pancreatitis: clinical and pathophysiological implications.
Mayer J; Rau B; Gansauge F; Beger HG
Gut; 2000 Oct; 47(4):546-52. PubMed ID: 10986216
[TBL] [Abstract][Full Text] [Related]
19. Endogenous plasma activated protein C levels and the effect of enoxaparin and drotrecogin alfa (activated) on markers of coagulation activation and fibrinolysis in pulmonary embolism.
Dempfle CE; Elmas E; Link A; Suvajac N; Liebe V; Janes J; Borggrefe M
Crit Care; 2011; 15(1):R23. PubMed ID: 21241489
[TBL] [Abstract][Full Text] [Related]
20. Mononuclear histocompatibility leukocyte antigen-DR expression in the early phase of acute pancreatitis.
Yu WK; Li WQ; Li N; Li JS
Pancreatology; 2004; 4(3-4):233-43. PubMed ID: 15166475
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
